Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Vazquez

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Clinical Genitourinary Cancer|June 21, 2024
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label StudyJoaquim Bellmunt, Pablo Maroto, Teresa Bonfill, et al.
Frontiers in Immunology|February 11, 2021
NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 DiabetesLaia Gomez-Muñoz, David Perna-Barrull, Adrian Villalba, et al.
Frontiers in Immunology|June 26, 2024
Corrigendum: Candidate biomarkers for the prediction and monitoring of partial remission in pediatric type 1 diabetesLaia Gomez-Muñoz, David Perna-Barrull, Josep M Caroz-Armayones, et al.
Frontiers in Immunology|March 14, 2022
Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 DiabetesLaia Gomez-Muñoz, David Perna-Barrull, Josep M Caroz-Armayones, et al.
Frontiers in Immunology|June 20, 2024
Corrigendum: NK cell subsets changes in partial remission and early stages of pediatric type 1 diabetesLaia Gomez-Muñoz, David Perna-Barrull, Adrian Villalba, et al.
Frontiers in Immunology|March 2, 2018
Phosphatidylserine-Liposomes Promote Tolerogenic Features on Dendritic Cells in Human Type 1 Diabetes by Apoptotic MimicrySilvia Rodriguez-Fernandez, Irma Pujol-Autonell, Ferran Brianso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2014
Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH studyAleix Prat, Giampaolo Bianchini, Marlene Thomas, et al.
Lancet (London, England)|February 2, 2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
The Lancet. Oncology|March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Clinical Genitourinary Cancer|June 21, 2024
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label StudyJoaquim Bellmunt, Pablo Maroto, Teresa Bonfill, et al.
Frontiers in Immunology|February 11, 2021
NK Cell Subsets Changes in Partial Remission and Early Stages of Pediatric Type 1 DiabetesLaia Gomez-Muñoz, David Perna-Barrull, Adrian Villalba, et al.
Frontiers in Immunology|June 26, 2024
Corrigendum: Candidate biomarkers for the prediction and monitoring of partial remission in pediatric type 1 diabetesLaia Gomez-Muñoz, David Perna-Barrull, Josep M Caroz-Armayones, et al.
Frontiers in Immunology|March 14, 2022
Candidate Biomarkers for the Prediction and Monitoring of Partial Remission in Pediatric Type 1 DiabetesLaia Gomez-Muñoz, David Perna-Barrull, Josep M Caroz-Armayones, et al.
Frontiers in Immunology|June 20, 2024
Corrigendum: NK cell subsets changes in partial remission and early stages of pediatric type 1 diabetesLaia Gomez-Muñoz, David Perna-Barrull, Adrian Villalba, et al.
Frontiers in Immunology|March 2, 2018
Phosphatidylserine-Liposomes Promote Tolerogenic Features on Dendritic Cells in Human Type 1 Diabetes by Apoptotic MimicrySilvia Rodriguez-Fernandez, Irma Pujol-Autonell, Ferran Brianso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2014
Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH studyAleix Prat, Giampaolo Bianchini, Marlene Thomas, et al.
Lancet (London, England)|February 2, 2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
The Lancet. Oncology|March 25, 2014
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.
Pageof 4